Malignant peritoneal mesothelioma: a review

Kim, Joseph; Bhagwandin, Shanel; Labow, Daniel M.

doi:10.21037/atm.2017.03.96

Cited by 123 publications

(154 citation statements)

References 85 publications

(122 reference statements)

Supporting

Mentioning

146

Contrasting

Unclassified

Order By: Relevance

“…On CT scan, MPM appears as a solid, heterogeneous, soft tissue mass with irregular margins that is enhanced by contrast or multiple small nodules involving the serosa. A diffuse distribution throughout the abdominal cavity, with no lymph node involvement or distant metastases, should raise suspicion of MPM since it tends to be more expansive than infiltrative [6]. The MPM differential diagnosis includes peritoneal carcinomatosis, serous peritoneal carcinoma, ovarian carcinoma, lymphomatosis, and tuberculous peritonitis.…”

Section: Discussionmentioning

confidence: 99%

Malignant Peritoneal Mesothelioma as a Rare Cause of Dyspeptic Complaints and Ascites: A Diagnostic Challenge

Sousa¹,

Pereira²,

Duarte³

et al. 2019

GE Port J Gastroenterol

View full text Add to dashboard Cite

Introduction: Malignant peritoneal mesothelioma (MPM) is a rare malignancy of the mesothelial cells in the peritoneum. The best-defined risk factor is asbestos exposure, but germline mutations in BAP1 also increase susceptibility to this tumor. The diagnosis of MPM is challenging since clinical manifestations are often nonspecific. Case Presentation: We describe a case of MPM in a 53-year-old former construction worker with prior asbestos exposure. The clinical presentation was a 3-month history of dyspeptic complaints. As initial workup, abdominal ultrasound and upper gastrointestinal endoscopy were performed. Chronic gastritis due to Helicobacter pylori was detected, which was promptly treated but without symptom relief. Abdominal ultrasound showed small volume ascites with hyperechogenic foci, which was later confirmed on computed tomography scan showing the presence of peritoneal nodules in the greater omentum and mesentery. A thorough investigation was conducted based on the suspicion of peritoneal carcinomatosis. A non-peritoneal primary tumor was not found. Ascitic cytology and im-

show abstract

Section: Discussionmentioning

confidence: 99%

Malignant Peritoneal Mesothelioma as a Rare Cause of Dyspeptic Complaints and Ascites: A Diagnostic Challenge

Sousa¹,

Pereira²,

Duarte³

et al. 2019

GE Port J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…In this study, we explored the regulation of PIAS3 expression in MM. MM is a highly‐aggressive thoracic cancer with poor prognosis and limited therapeutic options (Kim et al ., ). Genomic studies have revealed that MM is characterized by frequent mutations in tumor suppressor genes (Yap et al ., ), making the study of PIAS3 in this cancer highly relevant.…”

Section: Introductionmentioning

confidence: 97%

Post‐transcriptional regulation of PIAS3 expression by miR‐18a in malignant mesothelioma

et al. 2018

View full text Add to dashboard Cite

Protein inhibitor of activated STAT3 (PIAS3) is an endogenous suppressor of signal transducer and activator of transcription 3 (STAT3) signaling. By directly interacting with phosphorylated STAT3, PIAS3 can block the downstream transcriptional activity of STAT3, which is hyper‐activated in various cancers. We previously reported that in malignant mesothelioma (MM), low PIAS3 expression is associated with increased STAT3 activation and correlates with poor patient survival, yet the regulatory mechanism(s) governing PIAS3 expression in MM remain unclear. Here, we demonstrate that PIAS3 protein expression does not correlate with its mRNA level in MM cell lines, indicating that PIAS3 expression is regulated at a post‐transcriptional level. Inhibition of proteasomal degradation with MG132 (10 μm) or bortezomib (1 μm), alone and in combination, did not increase PIAS3 protein levels; furthermore, inhibition of protein synthesis by cycloheximide treatment did not decrease PIAS3 levels within 48 h, suggesting that PIAS3 expression is not actively regulated at a post‐translational level. To determine whether miRNA (miRs) can translationally regulate PIAS3 expression, we combined miR microarray analysis with bioinformatic screening to identify candidate miRs, in MM cell lines with low PIAS3 expression, followed by luciferase reporter assays to validate miR regulation of the PIAS3 3′UTR. We identified miR‐18a as a suppressor of PIAS3 expression that is upregulated in MM cells and whose inhibition can increase PIAS3 expression and suppress STAT3 activity. Moreover, we showed that miR‐18a inhibition can decrease MM cell viability and that its expression is negatively correlated with MM patient survival. Taken together, these results suggest that targeting miR‐18a may have therapeutic benefit in MM.

show abstract

“…The aim of HIPEC is to eliminate microscopic intraabdominal disease after CRS and thereby reduce the risk of recurrence. CRS combined with HIPEC is associated with a more favorable outcome than CRS alone when used for other peritoneal surface malignancies such as pseudomyxoma peritonei, peritoneal spreading from colorectal and appendiceal cancer, and malignant peritoneal mesothelioma . Moreover, morbidity has been reported to be acceptable.…”

Section: Introductionmentioning

confidence: 99%

“…CRS combined with HIPEC is associated with a more favorable outcome than CRS alone when used for other peritoneal surface malignancies such as pseudomyxoma peritonei, 5 peritoneal spreading from colorectal and appendiceal cancer, 6 and malignant peritoneal mesothelioma. 7 Moreover, morbidity has been reported to be acceptable. Whether the same applies to OC with peritoneal metastases remains controversial.…”

Section: Introductionmentioning

confidence: 99%

Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer

Mikkelsen

Christiansen

Petersen

et al. 2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Background and objectives: Hypertherm intraperitoneal chemotherapy (HIPEC) is increasingly used in the treatment of ovarian, tubal, and primary peritoneal cancer (OC). The aim was to evaluate short‐term morbidity of cytoreductive surgery (CRS) and carboplatin HIPEC. Methods: Prospective feasibility study performed from January 2016 to December 2017. Twenty‐five patients with primary OC (FIGO III‐IV) received upfront or interval CRS combined with carboplatin HIPEC at dose 800 mg/m 2. Primary outcome measurements: grade 3 to 5 adverse events within 30 days according to Common Terminology Criteria for Adverse Events. Secondary outcome measurements: reoperation rate, length of hospital stay, readmission rate, and time from surgery to systemic chemotherapy administration. Results: No deaths (grade 5) or grade 4 adverse events were observed. Eleven patients (44.0%) experienced at least one grade 3 adverse event, the most common being an infection (28.0%) and neutropenia (12.0%). The reoperation rate was 8.0%. The median hospital stay was 14 days (range 9‐25 days), and five patients (25.0%) were readmitted within 30 days after surgery. Median time from surgery to the administration of the first dose of systemic chemotherapy was 41 days (range 24‐81 days). Conclusion: Our small‐scale prospective study supports that CRS and carboplatin HIPEC used for primary advanced‐stage OC is feasible with acceptable morbidity.

show abstract

Malignant peritoneal mesothelioma: a review

Cited by 123 publications

References 85 publications

Malignant Peritoneal Mesothelioma as a Rare Cause of Dyspeptic Complaints and Ascites: A Diagnostic Challenge

Malignant Peritoneal Mesothelioma as a Rare Cause of Dyspeptic Complaints and Ascites: A Diagnostic Challenge

Post‐transcriptional regulation of PIAS3 expression by miR‐18a in malignant mesothelioma

Morbidity after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy with carboplatin used for ovarian, tubal, and primary peritoneal cancer

Contact Info

Product

Resources

About